PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Novavax to Present at the 25th Annual Piper Jaffray Healthcare Conference

ROCKVILLE, Md., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today that Stanley C. Erck, President and Chief Executive Officer, will present at the 25th Annual Piper Jaffray Healthcare Conference on December 3, 2013 at 1:30pm ET in New York City at the New York Palace Hotel.

A live webcast link for the presentation can be accessed via the company website at www.novavax.com under Investor Info/Events.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Novavax is involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea, PATH and recently acquired Isconova AB, a leading vaccine adjuvant company located in Sweden. Together, Novavax' network supports its global commercialization strategy to create real and lasting change in the biopharmaceutical and vaccinology fields. Additional information about Novavax is available on the company's website, novavax.com.

CONTACT: Barclay Phillips
         SVP, Chief Financial Officer and Treasurer
         Novavax, Inc.
         240-268-2000

Novavax logo

Novavax, Inc.